Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

(Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention ...

This was the stock's second consecutive day of gains.

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $93.07 which represents a slight increase of $0.15 or 0.16% from the prior close of $92.92. The stock opened at $92.36 and ...

As a result, life sciences companies are preparing for ... Dividend Yield as of December 28: 3.33% Gilead Sciences, Inc. (NASDAQ:GILD) is a global biopharmaceutical company that develops and ...

Gilead Sciences Inc (GILD) stock saw a decline, ending the day at $92.92 which represents a decrease of $-0.12 or -0.13% from the prior close of $93.04. The stock opened at $93.03 and touched a low of ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

Diversify Advisory Services LLC trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 16.3% during the ...

Gilead had been the darling of investors a ... has long promised to transform the life sciences, but today, we stand at a critical juncture where this potential is rapidly becoming a reality.

Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD – Research Report) and ...

(Reuters) - Gilead Sciences and the U.S. government have settled ... and deliver innovative therapeutics to people with life-threatening diseases." Spokespeople for the U.S. Department of ...